Clexane, 2000 IU (20 mg)/0.2 ml, solution for injection in pre-filled syringes
Clexane, 4000 IU (40 mg)/0.4 ml, solution for injection in pre-filled syringes
Clexane, 6000 IU (60 mg)/0.6 ml, solution for injection in pre-filled syringes
Clexane, 8000 IU (80 mg)/0.8 ml, solution for injection in pre-filled syringes
Clexane, 10,000 IU (100 mg)/1 ml, solution for injection in pre-filled syringes
Enoxaparin sodium
Clexane contains the active substance enoxaparin sodium. It belongs to a group of medicines called low molecular weight heparins or LMWH.
Clexane works in two ways:
Clexane can be used for:
Clexane should not be exchanged with other low molecular weight heparins such as nadroparin, tinzaparin, or dalteparin. This is because they are not exactly the same, differ in activity, and have different instructions for use.
Before starting Clexane, discuss with a doctor or pharmacist if:
In the case of patients taking doses higher than 210 mg/day, this medicine contains more than 24 mg of sodium (the main component of table salt) in each dose. This corresponds to 1.2% of the maximum recommended daily intake of sodium in the diet for adults.
Before starting this medicine and periodically during its use, the patient may undergo a blood test; its purpose is to check the number of platelets responsible for blood clotting and potassium in the patient's blood.
The safety and efficacy of Clexane have not been evaluated in children and adolescents.
Tell the doctor or pharmacist about all medicines the patient is currently taking or has recently taken, as well as any medicines the patient plans to take.
If the patient is scheduled for a lumbar puncture or surgery under spinal or epidural anesthesia, they should inform their doctor that they are taking Clexane.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult a doctor or pharmacist before taking this medicine.
In pregnant women with a mechanical heart valve, there may be an increased risk of blood clots. The doctor should discuss this with the patient.
Women who are breastfeeding or plan to breastfeed should consult a doctor before starting this medicine.
Clexane does not affect the ability to drive or use machines.
The doctor should document the trade name and batch number of the product used.
This medicine should always be used as directed by a doctor or pharmacist. If in doubt, consult a doctor or pharmacist.
Non-ST-segment elevation myocardial infarction (NSTEMI):
ST-segment elevation myocardial infarction (STEMI) in patients under 75 years of age:
STEMI in patients 75 years of age or older:
Patients undergoing percutaneous coronary intervention (PCI):
Self-administration of Clexane.
If the patient is able to self-administer Clexane, a doctor or nurse will demonstrate how to do it. Do not attempt to self-administer if the patient has not been trained. If in doubt, consult a doctor or nurse immediately. Administering the injection properly under the skin (so-called subcutaneous injection) can reduce pain and bruising at the injection site.
If the patient thinks they have used too much or too little Clexane, they should immediately inform their doctor, pharmacist, or nurse, even if they do not notice any problems. In case of accidental injection or ingestion of Clexane by a child, immediately go to the hospital emergency department.
If a dose of Clexane is missed, take it as soon as possible. Do not take a double dose to make up for the missed dose. Keeping a diary helps ensure that no dose of Clexane is missed.
It is important to continue administering Clexane injections until the doctor recommends stopping them. If treatment is stopped, a blood clot may form, which can be very dangerous.
If the patient has any further doubts about using this medicine, they should consult a doctor, pharmacist, or nurse.
Like all medicines, Clexane can cause side effects, although not everybody gets them.
nurseimmediately if the patient experiences symptoms of a severe allergic reaction (such as rash, difficulty breathing or swallowing, swelling of the face, lips, tongue, mouth, throat, or eyes).
If the patient experiences any of the following symptoms, they should stop using enoxaparin and seek medical attention immediately:
Like other similar medicines (used to reduce blood clotting), Clexane may cause bleeding. This can be life-threatening. In some cases, bleeding may not be immediately visible.
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
If side effects occur, including any side effects not listed in this leaflet, the patient should tell their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw.
Phone: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder or its representative in Poland.
Reporting side effects will help gather more information on the safety of this medicine.
Do not store above 25°C. Do not freeze.
Keep the medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the packaging. The expiration date refers to the last day of the specified month.
Do not use this medicine if the syringe is cracked, there are solid particles in the solution, or the solution has an abnormal color (see "What Clexane looks like and what the package contains").
Medicines should not be disposed of via wastewater or household waste. Ask a pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Clexane is a clear, colorless or yellowish solution for injection in a glass pre-filled syringe (with or without an automatic safety system).
Pack sizes: 2, 5, 6, 10, 12, 20, 24, 30, 50, 100 pre-filled syringes and in bulk packs of 3 x 10, 9 x 10, 100 x 10, and 200 x 10 pre-filled syringes.
Not all pack sizes may be marketed.
Sanofi Winthrop Industrie
82, Avenue Raspail
94250 Gentilly
France
Sanofi Winthrop Industrie
Boulevard Industriel, zone industrielle
76580 Le Trait
France
Sanofi Winthrop Industrie
180, rue Jean Jaurès
94 700 Maisons-Alfort
France
CHINOIN Pharmaceutical and Chemical Works Private Co. Ltd.
Csanyikvölgy Site
Miszkolc, Csanyikvölgy
H-3510
Hungary
Sanofi-Aventis Private Co. Ltd
Budapest Logistics and Distribution Platform
Bdg. DC5, Campona utca1.
Budapest, 1225
Hungary
Sanofi-Aventis GmbH
Turm A, 29. OG, Wienerbergstraße 11
1100 Vienna
Austria
Sanofi-Aventis Deutschland GmbH
Industriepark Höchst-Brüningstraße 50
65926 Frankfurt am Main
Germany
Sanofi Sp. z o.o.
ul. Marcina Kasprzaka 6
01-211 Warsaw
phone: +48 22 280 00 00
Detailed information about this medicine is available on the website of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products (www.urpl.gov.pl)
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.